



Hot Topic

References

COVID-19 Vaccine Tracker

Method	Developer / Manufacturer	Doses (Days)	Efficacy (%)	Storage (°C)	EU / UK approval status
RNA	Pfizer BIONTECH	1: 0 2: 21	95.0 Based on 170 cases	-80 to -60 2 to 8 For 5 days	<ul style="list-style-type: none"> EU: 21 Dec 2020 <i>Approved for use</i> UK: 02 Dec 2020 <i>Approved for use</i>
RNA	moderna NIH NIAID	1: 0 2: 28	94.1 Based on 196 cases	-25 to -15 2 to 8 For 30 days	<ul style="list-style-type: none"> EU: 06 Jan 2021 <i>Approved for use</i> UK: 08 Jan 2021 <i>Approved for use</i>
NRV	AstraZeneca UNIVERSITY OF OXFORD	1: 0 2: 28+	70.4 Based on 131 cases	2 to 8	<ul style="list-style-type: none"> EU: 29 Jan 2021 <i>Approved for use</i> UK: 30 Dec 2020 <i>Approved for use</i>
NRV	Janssen	1: 0	66.0 Based on 468 cases	2 to 8 For ≥3 months	<ul style="list-style-type: none"> EU: 11 Mar 2021 <i>Approved for use</i> UK: Early 2021
PSU	NOVAVAX	1: 0 2: 21	89.3 Based on 62 cases	2 to 8	<ul style="list-style-type: none"> EU: 03 Feb 2021 <i>Rolling review initiated (EMA)</i> UK: 2021
RNA	UREVAC	1: 0 2: 28	N/A Efficacy data expected Q1 2021	Below -60	<ul style="list-style-type: none"> EU: 12 Feb 2021 <i>Rolling review initiated (EMA)</i> UK: Unknown
NRV	GAMALEYA RESEARCH INSTITUTE (Sputnik V)	1: 0 2: 21	91.6 Based on 78 cases	2 to 8	<ul style="list-style-type: none"> EU: 04 Mar 2021 <i>Rolling review initiated (EMA)</i> UK: Unknown



Note: Safety data will be provided once widely available

NRV, non-replicating viral vector; PSU, protein subunit; RNA, ribonucleic acid

Key:

Click for further details
 Click for more information




← Back to Main Menu

COVID-19 Vaccine Tracker

Method	Developer / Manufacturer	Doses (Days)	Efficacy (%)	Storage (°C)	Approval status
RNA	Pfizer BIONTECH				
RNA	moderna NIH NIAID				
NRV	AstraZeneca UNIVERSITY OF OXFORD	1: 0 2: 28+	70.4 Based on 131 cases	2 to 8	EU: 29 Dec 2020 UK: 30 Dec 2020 Approved for use
NRV	Janssen	1	66.0 Based on 468 cases	2 to 8 For ≥3 months	EU: 11 Mar 2021 UK: Early 2021 Approved for use
PSU	NOVAVAX	1: 0 2: 21	89.3 Based on 62 cases	2 to 8	EU: 03 Feb 2021 UK: 2021 Rolling review initiated (EMA)
RNA	UREVAC				
NRV	GAMALEYA RESEARCH INSTITUTE (Sputnik V)	1: 0 2: 21	91.6 Based on 78 cases	2 to 8	EU: 04 Mar 2021 UK: Unknown Rolling review initiated (EMA)

RNA vaccines consist of RNA encoding the **spike protein** of SARS-CoV-2 and are typically packaged in lipid envelopes






← Back to Main Menu

COVID-19 Vaccine Tracker

Method	Developer / Manufacturer	Doses (Days)	Efficacy (%)	Storage (°C)	EU / UK approval status
RNA		1: 0 2: 21	95.0 Based on 170 cases	-80 to -60 2 to 8 For 5 days	<ul style="list-style-type: none"> EU: 21 Dec 2020 - Approved for use UK: 02 Dec 2020 - Approved for use
RNA		1: 0 2: 28	94.1 Based on 196 cases	-25 to -15 2 to 8 For 30 days	<ul style="list-style-type: none"> EU: 06 Jan 2021 - Approved for use UK: 08 Jan 2021 - Approved for use
NRV					
NRV					
PSU		1: 0 2: 21	62 cases		Rolling review initiated (EMA)
RNA		1: 0 2: 28	N/A Efficacy data expected Q1 2021	Below -60	<ul style="list-style-type: none"> EU: 05 Dec 2020 - Rolling review initiated (EMA) UK: Unknown
NRV					

Non-replicating viral vector vaccines cannot cause disease but contain the gene for the spike protein of SARS-CoV-2






← Back to Main Menu

COVID-19 Vaccine Tracker

Method	Developer / Manufacturer	Doses (Days)	Efficacy (%)	Storage (°C)	EU / UK approval status
RNA	Pfizer / BIONTECH	1: 0, 2: 21	95.0 Based on 170 cases	-80 to -60 2 to 8 For 5 days	EU: 21 Dec 2020 - Approved for use UK: 02 Dec 2020 - Approved for use
RNA	moderna / NIH NIAID	1: 0, 2: 28	94.1 Based on 196 cases	-25 to -15 2 to 8 For 30 days	EU: 06 Jan 2021 - Approved for use UK: 08 Jan 2021 - Approved for use
NRV	AstraZeneca / UNIVERSITY OF OXFORD	1: 0, 2: 28+	70.4 Based on 131 cases	2 to 8	EU: 29 Jan 2021 - Approved for use UK: 30 Dec 2020 - Approved for use
NRV	Janssen	1: 1	66.0 Based on 468 cases	2 to 8	EU: 09 Jan 2021 - Approved for use UK: 08 Jan 2021 - Approved for use
PSU	NOVAVAX	Protein subunit vaccine: recombinant spike-protein-based vaccines			
RNA	UREVAC	1: 0, 2: 28	N/A Efficacy data expected Q1 2021	Below -60	Rolling review initiated (EMA)
NRV	GAMALEYA RESEARCH INSTITUTE (Sputnik V)	1: 0, 2: 21	91.6 Based on 78 cases	2 to 8	EU: 04 Mar 2021 - Rolling review initiated (EMA) UK: Unknown





← Back to Main Menu

COVID-19 Vaccine Tracker

i UK government has approved a delay between doses of up to 12 weeks **X**

Method	Developer / Manufacturer	Doses (Days)	Efficacy (%)	Based on (Cases)	Delay (Days)	EU / UK approval status
RNA	Pfizer / BIONTECH	1: 0 2: 21	95.0	Based on 170 cases	2 to 8 For 5 days	<ul style="list-style-type: none"> EU: 21 Dec 2020 - Approved for use UK: 02 Dec 2020 - Approved for use
RNA	moderna / NIH NIAID	1: 0 2: 28	94.1	Based on 196 cases	-25 to -15 2 to 8 For 30 days	<ul style="list-style-type: none"> EU: 06 Jan 2021 - Approved for use UK: 08 Jan 2021 - Approved for use
NRV	AstraZeneca / UNIVERSITY OF OXFORD	1: 0 2: 28+	70.4	Based on 131 cases	2 to 8	<ul style="list-style-type: none"> EU: 29 Jan 2021 - Approved for use UK: 30 Dec 2020 - Approved for use
NRV	janssen	1: 1	66.0	Based on 468 cases	2 to 8 For ≥3 months	<ul style="list-style-type: none"> EU: 11 Mar 2021 - Approved for use UK: Early 2021
PSU	NOVAVAX	1: 0 2: 21	89.3	Based on 62 cases	2 to 8	<ul style="list-style-type: none"> EU: 03 Feb 2021 - Rolling review initiated (EMA) UK: 2021
RNA	UREVAC	1: 0 2: 28	N/A	Efficacy data expected Q1 2021	Below -60	<ul style="list-style-type: none"> EU: 12 Feb 2021 - Rolling review initiated (EMA) UK: Unknown
NRV	GAMALEYA RESEARCH INSTITUTE (Sputnik V)	1: 0 2: 21	91.6	Based on 78 cases	2 to 8	<ul style="list-style-type: none"> EU: 04 Mar 2021 - Rolling review initiated (EMA) UK: Unknown



← Back to Main Menu

COVID-19 Vaccine Tracker

Method	Developer / Manufacturer	Doses (Days)	Efficacy (%)	Storage (°C)	EU / UK approval status
RNA	Pfizer BIONTECH	1: 0 2: 21	95.0 Based on 170 cases	-80 to -60 2 to 8 For 5 days	<ul style="list-style-type: none"> EU: 21 Dec 2020 - Approved for use UK: 02 Dec 2020 - Approved for use
RNA	moderna NIH NIAID	1: 0 2: 28	94.1 Based on 196 cases	-25 to -15 2 to 8 For 30 days	<ul style="list-style-type: none"> EU: 06 Jan 2021 - Approved for use UK: 08 Jan 2021 - Approved for use
NRV	AstraZeneca UNIVERSITY OF OXFORD	1: 0 2: 28+	70.4 Based on 131 cases	2 to 8	<ul style="list-style-type: none"> EU: 29 Jan 2021 - Approved for use UK: 01 Dec 2020 - Approved for use
NRV	Janssen	1: 0	66.0 Based on 468 cases	2 to 8 For ≥3 months	<ul style="list-style-type: none"> EU: 11 Mar 2021 - Approved for use UK: Early 2021
PSU	NOVAVAX	1: 0 2: 21	89.3 Based on 62 cases	2 to 8	<ul style="list-style-type: none"> EU: 03 Feb 2021 - Rolling review initiated (EMA) UK: 2021
RNA	UREVAC	1: 0 2: 28	N/A Efficacy data expected Q1 2021	Below -60	<ul style="list-style-type: none"> EU: 12 Feb 2021 - Rolling review initiated (EMA) UK: Unknown
NRV	GAMALEYA RESEARCH INSTITUTE (Sputnik V)	1: 0 2: 21	91.6 Based on 78 cases	2 to 8	<ul style="list-style-type: none"> EU: 04 Mar 2021 - Rolling review initiated (EMA) UK: Unknown


i 62% in the standard dose cohort; 90% in the lower dose cohort **x**





← Back to Main Menu

COVID-19 Vaccine Tracker

Method	Developer / Manufacturer	Doses (Days)	Efficacy (%)	Storage (°C)	EU / UK approval status
RNA	Pfizer BIONTECH	1: 0 2: 21	95.0 Based on 170 cases	-80 to -60 2 to 8 For 5 days	EU: 21 Dec 2020 - Approved for use UK: 02 Dec 2020 - Approved for use
RNA	moderna NIH NIAID	1: 0 2: 28	94.1 Based on 196 cases	-25 to -15 2 to 8 For 30 days	EU: 06 Jan 2021 - Approved for use UK: 08 Jan 2021 - Approved for use
NRV	AstraZeneca UNIVERSITY OF	1: 0 2: 28	70.4 Based on 196 cases	2 to 8	EU: 29 Jan 2021 - Approved for use
PSU	NOVAVAX	1: 0 2: 21	89.3 Based on 62 cases	2 to 8	EU: 03 Feb 2021 - Rolling review initiated (EMA) UK: 2021
RNA	UREVAC	1: 0 2: 28	N/A Efficacy data expected Q1 2021	Below -60	EU: 12 Feb 2021 - Rolling review initiated (EMA) UK: Unknown
NRV	GAMALEYA RESEARCH INSTITUTE (Sputnik V)	1: 0 2: 21	91.6 Based on 78 cases	2 to 8	EU: 04 Mar 2021 - Rolling review initiated (EMA) UK: Unknown

 Is there a link between vaccination for COVID-19 and developing blood clots?
[Click here to find out more](#)

Janssen has announced their decision to proactively delay the rollout of the vaccine in the EU while blood clot link investigations continue  



References



Back to
Main Menu

1. Polack FP, et al. N Engl J Med 2020; DOI: [10.1056/NEJMoa2034577](https://doi.org/10.1056/NEJMoa2034577)
2. Pfizer-BioNTech COVID-19 Vaccine. <https://www.cvdvaccine-us.com/product-storage-and-dry-ice> [Accessed December 2020]
3. <https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu>
4. <https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19>
5. Baden LR, et al. N Engl J Med 2020 Dec 30; DOI: [10.1056/NEJMoa2035389](https://doi.org/10.1056/NEJMoa2035389)
6. <https://www.modernatx.com/covid19vaccine-eua/providers/storage-handling>
7. <https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu>
8. <https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna>
9. Voysey M, et al. Lancet 2020 Dec 8; DOI: [10.1016/S0140-6736\(20\)32661-1](https://doi.org/10.1016/S0140-6736(20)32661-1)
10. <https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu>
11. <https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca>
12. ClinicalTrials.gov. NCT04505722. Available at: <https://clinicaltrials.gov/ct2/show/NCT04505722>
13. https://www.janssen.com/emea/sites/www_janssen_com_emea/files/johnson_johnson_announces_single-shot_janssen_covid-19_vaccine_candidate_met_primary_endpoints_in_interim_analysis_of_its_phase_3_ensemble_trial.pdf
14. <https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate>
15. <https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-janssen-authorisation-eu>
16. <https://www.janssen.com/uk/road-vaccine>
17. ClinicalTrials.gov. NCT04583995. Available at: <https://clinicaltrials.gov/ct2/show/NCT04583995>
18. ClinicalTrials.gov. NCT04611802. Available at: <https://clinicaltrials.gov/ct2/show/NCT04611802>
19. <https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3>
20. <https://ir.novavax.com/news-releases/news-release-details/novavax-announces-publication-phase-1-data-covid-19-vaccine>
21. <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-vaccines-covid-19-medicines-under-evaluation>
22. https://www.curevac.com/wp-content/uploads/2020/12/20201214-CureVac-HERALD-Clinical-Trial-Protocol-of-Phase-2b_3_CVnCoV.pdf
23. <https://www.curevac.com/en/covid-19/#clinical-studies>
24. Logunov D, et al. Lancet 2021;397:671–681.
25. <https://sputnikvaccine.com/about-vaccine/>

